Review: Antitumor necrosis factor-α-directed therapies are recommended for NSAID-refractory spondyloarthritis

May 2004
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p71
Academic Journal
This article presets a study, which examines the optimal use of biologic response modifiers, in patients with spondyloarthritis. Studies were selected if they were randomized, placebo-controlled trials or nonrandomized clinical trials evaluating anti-tumor necrosis factor agents in patients with spondyloarthritis. A consensus group graded the evidence according to the guidelines of the U.S. Agency for Healthcare Research and Quality, and recommendations were made. In patients with spondyloarthritis who have not responded to therapy with nonsteroidal antiinflammatory drugs or methotrexate, antitumor necrosis factor-α agents provide effective symptom control and improve physical function and quality of life.


Related Articles

  • Skeletal tuberculosis mimicking seronegative spondyloarthropathy. Hammoudeh, Mohammed; Khanjar, Izzat // Rheumatology International;Jan2004, Vol. 24 Issue 1, p50 

    Skeletal tuberculosis (TB) is still a common problem in developing countries. It is a postprimary manifestation of TB and appears usually with fever, pain, tenderness, and limitation of motion at the involved site. We present a patient with a clinical course very suggestive of seronegative...

  • Anti-Tumor Necrosis Factor-α Therapy in Undifferentiated Spondyloarthritis (USpA). Hsien-Tzung Liao; Chun-Hsiung Chen; Wei-Sheng Chen; Hui-Ting Lee; Chang-Youh Tsai; Chung-Tei Chou // Current Rheumatology Reviews;2009, Vol. 5 Issue 3, p174 

    Undifferentiated spondyloarthritis (USpA) include incomplete forms or early phases of definite seronegative spondyloarthritis (SpA) and cases of spondyloarthritis that remain undifferentiated. The treatment of SpA is more conditioned by the disease localization. Non-steroidal anti-inflammatory...

  • Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based survey. Zochling, Jane; Bohl-Bühler, Martin H. J.; Baraliakos, Xenofon; Feldtkeller, Ernst; Braun, Jürgen // Clinical Rheumatology;Dec2006, Vol. 25 Issue 6, p794 

    The objective of the study is to describe the use, clinical efficacy, and toxicity of nonsteroidal anti-inflammatory drug (NSAID) therapy in patients with ankylosing spondylitis (AS). A cross-sectional population study of 1,080 AS patients was carried out by a written questionnaire in the year...

  • EXPOSE: INFLAMMATORY SPINE ARTHRITIS.  // Total Health;Oct/Nov2004, Vol. 26 Issue 5, Special Section p6 

    Presents information on spondyloarthropathies, a form of arthritis which include arthritis-like conditions in the spine. Details of several conditions that are related to inflammatory spine arthritis; Background on the important factor in the management of spondyloarthropathies; Non-steroidal...

  • The Changing Face of Spondyloarthropathies Under TNF α Blockade. Elkayam, Ori; Litinsky, Irena; Levartovsky, David; Caspi, Dan // Open Rheumatology Journal;2008, Vol. 2, p53 

    Objectives: Tumor necrosis factor alpha (TNF-α) therapy has been implicated in the development of autoimmune diseases. Our aim was to describe three patients with spondyloarthropathies who responded to infliximab, a chimeric monoclonal antibody specific for TNF-α, but developed new...

  • A Pilot Study of the Safety and Tolerability of Etanercept in Patients with Alcoholic Hepatitis. Menon, K. V. Narayanan; Stadheim, Linda; Kamath, Patrick S.; Wiesner, Russell H.; Gores, Gregory J.; Peine, Craig J.; Shah, Vijay // American Journal of Gastroenterology;Feb2004, Vol. 99 Issue 2, p255 

    BACKGROUND: Alcoholic hepatitis is a cause of major morbidity and mortality, and effective therapeutic regimens to treat this condition are lacking. Both experimental and clinical evidence indicates that tumor necrosis factor alpha (TNF), and the downstream cytokine interleukin-6 (IL-6),...

  • Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis. K. Gadsby; C. Deighton // Rheumatology;Mar2007, Vol. 46 Issue 3, p439 

    Objective. We present the results of the response to anti-tumour necrosis factor (anti-TNF) of 30 ankylosing spondylitis (AS) patients where we have complied with the BSR guidelines.Method. All patients had pre-assessments of Bath AS Disease Activity Index (BASDAIs) at two points a month apart...

  • Therapy with biological agents in juvenile-onset ankylosing spondylarthritis. Chiran, D. A.; Moraru, Eovelina; Ailioaie, Laura Marinela; Ailioaie, C. // Romanian Journal of Pediatrics;2012, Vol. 61 Issue 3, p308 

    Ankylosing spondylarthritis is an immune-mediated inflammatory disease, which includes axial and peripheral arthritis, inflammation of the site where tendons and joint capsules attaches to the bone and degeneration of the sacroiliac joint and the spinal cord joints, leading to progressive spinal...

  • TERAPIA CU AGENÅ¢I BIOLOGICI ÃŽN SPONDILARTRITA ANKILOZANTÄ‚ CU DEBUT JUVENIL. Chiran, D. A.; Moraru, Eovelina; Ailioaie, Laura Marinela; Ailioaie, C. // Romanian Journal of Pediatrics;2012, Vol. 61 Issue 3, p306 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics